A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.

doi:10.1158/1078-0432.CCR-25-0571

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 4 Feb 2026

Lynce Filipa, Graham Noah, Kochupurakkal Bose S, Nguyen Huy, Bychkovsky Brittany, Poorvu Philip D, Attaya Victoria, Davis Raechel, DiLullo Molly, D'Andrea Alan D, Garber Judy E, Garg Kavita, Lim Lee P, Li Mark, Paweletz Cloud P, Tayob Nabihah, Shapiro Geoffrey I, Tolaney Sara M

Abstract excerpt

PURPOSE: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2-mutated HER2-negative metastatic breast cancer. PATIENTS AND METHODS: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor-naïve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Neoplasm Metastasis

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 41335237
DOI: 10.1158/1078-0432.CCR-25-0571

Genes

BRCA1
BRCA2
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.PMID 41335237Read ↗

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.Semantic proximity Read ↗

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Semantic proximity Read ↗

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.Semantic proximity Read ↗

Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancerSemantic proximity Read ↗

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant CancersSemantic proximity Read ↗

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.Semantic proximity Read ↗

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation CarriersSemantic proximity Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialSemantic proximity Read ↗

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 studySemantic proximity Read ↗

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.Semantic proximity Read ↗

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.